Invesco BuyBack Achievers ETF (PKW) Touches $61.02 Formed H&S; Becton Dickinson and Company (BDX) SI Decreased By 8.73%

September 14, 2018 - By Jacob Reddy

Becton, Dickinson and Company (NYSE:BDX) Logo

Invesco BuyBack Achievers ETF (PKW) formed inverse H&S with $64.68 target or 6.00% above today’s $61.02 share price. Invesco BuyBack Achievers ETF (PKW) has $1.29B valuation. The ETF increased 0.20% or $0.12 during the last trading session, reaching $61.02. About 4,654 shares traded. Invesco BuyBack Achievers ETF (NASDAQ:PKW) has risen 12.14% since September 14, 2017 and is uptrending. It has underperformed by 3.48% the S&P500.

Becton Dickinson and Company (NYSE:BDX) had a decrease of 8.73% in short interest. BDX’s SI was 4.16M shares in September as released by FINRA. Its down 8.73% from 4.55 million shares previously. With 624,100 avg volume, 7 days are for Becton Dickinson and Company (NYSE:BDX)’s short sellers to cover BDX’s short positions. The stock increased 0.06% or $0.15 during the last trading session, reaching $261.15. About 75,633 shares traded. Becton, Dickinson and Company (NYSE:BDX) has risen 27.77% since September 14, 2017 and is uptrending. It has outperformed by 12.15% the S&P500. Some Historical BDX News: 19/03/2018 – BDX TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL; 22/03/2018 – U.S FDA SAYS MAGELLAN’S LEAD TEST SYSTEMS CAN CONTINUE TO BE USED WITH BLOOD SAMPLES FROM A FINGER OR HEEL STICK; 27/04/2018 – Becton Dickinson Names Bill Tozzi Interim President of Interventional Segment; 11/05/2018 – U.S. investigates bloodstream infections for link to heparin syringes; 17/05/2018 – Fitch Rates Becton, Dickinson and Company’s Senior Notes ‘BBB-‘; Outlook Stable; 26/04/2018 – FDA: Becton Dickinson & Company- BD Vacutainer® Push Button Blood Collection Set 0.8 x 19 mm x 305 mm 21G x ® x 12 Catalog; 03/05/2018 – Becton Dickinson Prior FY18 Rev Growth View Was 30%-31%; 23/03/2018 – FDA: BDX RECALLS VACUTAINER EDTA BLOOD COLLECTION TUBES; 11/05/2018 – Omers Adds Brookfield Business, Exits Becton Dickinson: 13F; 27/04/2018 – Becton Dickinson: John Groetelaars to Leave to Join Another Company

Among 3 analysts covering Becton Dickinson (NYSE:BDX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Becton Dickinson had 4 analyst reports since April 10, 2018 according to SRatingsIntel. As per Tuesday, April 10, the company rating was upgraded by Citigroup. The firm has “Buy” rating by Citigroup given on Wednesday, August 8. The stock of Becton, Dickinson and Company (NYSE:BDX) earned “Buy” rating by J.P. Morgan on Thursday, June 21. JP Morgan upgraded the stock to “Overweight” rating in Thursday, June 21 report.

Becton, Dickinson and Company develops, makes, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company has market cap of $69.88 billion. It operates in two divisions, BD Medical and BD Life Sciences. It has a 107.07 P/E ratio. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems.

Since May 7, 2018, it had 1 buy, and 2 sales for $6.80 million activity. Another trade for 10,209 shares valued at $2.31 million was sold by Shabshab Nabil. Shares for $4.60 million were sold by Conroy Alexandre on Monday, May 21. 500 shares were bought by Melcher David F, worth $112,535 on Monday, May 7.

Investors sentiment decreased to 0.88 in Q2 2018. Its down 0.17, from 1.05 in 2018Q1. It is negative, as 38 investors sold Becton, Dickinson and Company shares while 403 reduced holdings. 87 funds opened positions while 301 raised stakes. 222.19 million shares or 1.10% more from 219.77 million shares in 2018Q1 were reported. Peak6 Invests Limited Partnership has invested 0.01% in Becton, Dickinson and Company (NYSE:BDX). Fire Group holds 0.19% or 2,000 shares in its portfolio. Boston Family Office Llc reported 13,107 shares stake. Lifeplan Fin Group reported 175 shares. Ny State Teachers Retirement has invested 0.24% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Moreover, Hanson Mcclain Incorporated has 0% invested in Becton, Dickinson and Company (NYSE:BDX) for 19 shares. Iowa State Bank owns 0.1% invested in Becton, Dickinson and Company (NYSE:BDX) for 860 shares. Greenleaf Tru holds 0.01% or 1,939 shares. Quantitative Systematic Strategies Lc reported 2,650 shares. Sector Pension Board stated it has 0.02% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Gamco Invsts Et Al stated it has 32,326 shares or 0.05% of all its holdings. Barnett & owns 80 shares or 0.01% of their US portfolio. Bank Of Montreal Can stated it has 0.14% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Bourgeon Lc invested in 22,032 shares or 2.84% of the stock. One Association reported 0.48% in Becton, Dickinson and Company (NYSE:BDX).

More recent Becton, Dickinson and Company (NYSE:BDX) news were published by: Seekingalpha.com which released: “Thermo Fisher to acquire advanced bioprocessing business from BD” on September 07, 2018. Also Investorplace.com published the news titled: “5 Medical Device Stocks With Impressive Staying Power” on September 13, 2018. Streetinsider.com‘s news article titled: “Becton Dickinson and Company (BDX) Releases Statement & Prelim. EPS Contribution on Sale of Advanced …” with publication date: September 07, 2018 was also an interesting one.

Becton, Dickinson and Company (NYSE:BDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts